Arbutus Biopharma (ABUS) Stock Forecast & Price Target

Arbutus Biopharma's strong pipeline, particularly the RNAi therapeutic imdusiran (AB-729), is highlighted by its promising ability to achieve significant reductions in HBsAg levels for chronic hepatitis B virus patients, supporting its potential as a key component in combination therapy. The drug's demonstrated safety and tolerability, with no serious adverse events reported, further bolster confidence in its clinical advancement and market acceptance. Additionally, the projected risk-adjusted per share value of imdusiran at approximately $3.84, combined with a potential peak revenue forecast of $1.56 billion globally by 2038, underlines a strong financial outlook for the company.

Arbutus Biopharma's stock outlook is negatively influenced by potential challenges in demonstrating the clinical efficacy of its key therapies, including imdusiran (AB-729) and AB-101, due to competitive pressures and the risk of trial failures. The company's reliance on specific patient recruitment for clinical programs may hinder its ability to achieve necessary endpoints, while advancements in treatment methodologies could render its current offerings obsolete. Furthermore, emerging safety concerns related to RNAi therapeutic exposure in the liver pose both short-term and long-term risks that could affect investor confidence.